ClinicalTrials.gg
TerminatedNCT03358290CLEAR-PSUpdated Aug 6, 2021Results posted

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of JTE-051 and Placebo in Plaque Psoriasis and Skin Diseases, sponsored by Akros Pharma Inc.. Terminated at 16 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-08-06.

Primary conditionPsoriasisRegistry: Skin DiseasesReclassifiedWhy we changed it
Registry
Skin Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Psoriasis
Why
  1. The study's listed conditions name Psoriasis, a narrower term within Skin Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 2, Interventional, and Treatment

Why this study was terminated
Difficulty faced with enrollment in the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
594th of 673
13 · median 77
Started
2017
with 49 others
Phase 2
200 of 764
5 open now
Registered
465th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 594th largest by enrollment of the 673 interventional ones that give a count, is one of 50 that started in 2017, is one of 200 in phase 2, and was the 465th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis
  • Skin Diseases

Browse trials for

Keywords

  • JTE-051
  • Psoriasis
04

In context

Psoriasis Reclassified

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

This study's enrollment of 13 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

Akros Pharma Inc. is the lead sponsor of 25 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

First submitted before Akros Pharma Inc. became part of Shionogi.

Compared within Psoriasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with moderate to severe plaque psoriasis at least 6 months prior to Visit 1
  • Plaque-type psoriasis covering ≥10% of body surface area (BSA) at Visit 1 and Visit 2;
  • Psoriasis Area and Severity Index (PASI) score ≥12 at Visit 1 and Visit 2;
  • Static Physician's Global Assessment (sPGA) score ≥3 at Visit 1 and Visit 2;
  • (BMI) ≤40 at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Medical history of treatment failure to any systemic agents for plaque psoriasis;
  • Presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis or other skin conditions at (e.g., clinically-significant eczema or severe acne) that could interfere with study evaluations at Visit 1;
  • Presence or history of any itch due to underlying conditions other than plaque psoriasis which cause or influence pruritus of the skin (e.g., drug induced pruritus, significant other systemic diseases with itch) within 12 months prior to Visit 1;
  • History of a clinically-significant infection (e.g., that required oral antimicrobial therapy) within 8 weeks prior to Visit 2;
  • History of infections requiring hospitalization or parenteral antibiotic, antiviral, antifungal or antiparasitic therapy within 6 months prior to Visit 2 and no history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis);
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    JTE-051 Dose 1

    One dose of study drug by mouth daily for 12 weeks

    Drug: JTE-051

  • Experimental
    JTE-051 Dose 2

    One dose of study drug by mouth daily for 12 weeks

    Drug: JTE-051

  • Experimental
    JTE-051 Dose 3

    One dose of study drug by mouth daily for 12 weeks

    Drug: JTE-051

  • Experimental
    JTE-051 Dose 4

    One dose of study drug by mouth daily for 12 weeks

    Drug: JTE-051

  • Experimental
    Placebo

    One dose of study drug by mouth daily for 12 weeks

    Drug: Placebo

Interventions

  • DrugJTE-051

    Active drug tablets containing JTE-051

  • DrugPlacebo

    Placebo tablets identical in appearance to the active drug tablets

07

What researchers measure

Primary outcomes

  1. Proportion of Subjects Achieving a Minimum 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI-75) by End-of-treatment (EOT).

    The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-75 response rate is defined as at least 75 percent (%) reduction in PASI score relative to Baseline.

    Time frame: Up to 12 Weeks

Secondary outcomes

  1. Percent Change From Baseline in PASI Score

    The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percent change was calculated by taking the Week 12 PASI score and subtracting the baseline PASI, and dividing by the baseline PASI, then multiplying by 100 to get the percent change from baseline.

    Time frame: Week 12

  2. Proportion of Subjects Achieving PASI-50 (50% Improvement From Baseline in PASI)

    The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-50 response rate is defined as at least 50 percent (%) reduction in PASI score relative to Baseline.

    Time frame: Week 12

  3. Proportion of Subjects Achieving PASI-90 (90% Improvement From Baseline in PASI)

    The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-90 response rate is defined as at least 90 percent (%) reduction in PASI score relative to Baseline.

    Time frame: Week 12

  4. Proportion of Subjects Achieving PASI-100 (100% Improvement From Baseline in PASI)

    The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-100 response rate is defined as 100 percent (%) reduction in PASI score relative to Baseline.

    Time frame: Week 12

  5. Proportion of Subjects Who Achieved Static Physician's Global Assessment (sPGA) Score of 0 or 1

    The sPGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the redness, thickness and scaling across all psoriatic lesions. Average redness, thickness and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score is calculated as average of the 3 severity (redness, thickness and scaling) scores and rounded to the nearest whole number score to determine the sPGA score (0=cleared; 1=minimal; 2=mild; 3=moderate; and 4=severe). For this outcome measure, a score of 0 means no symptoms of psoriasis and a score of 1 means minimal symptoms of psoriasis.

    Time frame: Week 12

  6. Change From Baseline in Static Physician's Global Assessment (sPGA) Score

    The sPGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the redness, thickness and scaling across all psoriatic lesions. Average redness, thickness and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score is calculated as average of the 3 severity (redness, thickness and scaling) scores and rounded to the nearest whole number score to determine the sPGA score (0=cleared; 1=minimal; 2=mild; 3=moderate; and 4=severe). Change from baseline to Week 12 in sPGA was calculated by taking the Week 12 sPGA and subtracting the baseline sPGA.

    Time frame: Week 12

  7. Percent Change From Baseline in Psoriasis Body Surface Area (BSA)

    The total body surface area (BSA) affected by plaque-type psoriasis was obtained from the percentages of areas affected, including head, trunk, upper limbs and lower limbs. Each reported percentage was multiplied by its respective body region corresponding factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) and the resulting 4 values were added up to obtain the total psoriasis BSA (Range: 0 to 100). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region surface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs. Percent change from baseline to Week 12 in BSA was calculated by taking the Week 12 BSA and subtracting the baseline BSA, then dividing by the baseline BSA and multiplying by 100. A negative change from baseline at Week 12 indicates a reduction in the Psoriasis BSA compared to the baseline.

    Time frame: Week 12

  8. Change From Baseline in the Skindex-16 Overall Score

    Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Overall scale score is an average of 16 items expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Overall Score was calculated by taking the Week 12 Skindex-16 Overall Score and subtracting the baseline Skindex-16 Overall Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.

    Time frame: Week 12

  9. Change From Baseline in the Skindex-16 Symptoms Scale Score

    Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Symptoms scale score is an average of items 1 to 4 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Symptoms Scale Score was calculated by taking the Week 12 Skindex-16 Symptoms Scale Score and subtracting the baseline Skindex-16 Symptoms Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.

    Time frame: Week 12

  10. Change From Baseline in the Skindex-16 Emotions Scale Score

    Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Emotions scale score is an average of items 5 to 11 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Emotions Scale Score was calculated by taking the Week 12 Skindex-16 Emotions Scale Score and subtracting the baseline Skindex-16 Emotions Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.

    Time frame: Week 12

  11. Change From Baseline in the Skindex-16 Functioning Scale Score

    Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Functioning scale score is an average of items 12 to 16 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Functioning Scale Score was calculated by taking the Week 12 Skindex-16 Functioning Scale Score and subtracting the baseline Skindex-16 Functioning Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.

    Time frame: Week 12

  12. Number of Subjects With Treatment-emergent Adverse Events

    Subjects in the Safety Population (13, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The study was terminated early as per the Sponsor decision. All randomized subjects were included in the Safety Population.

    Time frame: Up to 16 Weeks

  13. JTE-051 Trough Plasma Concentrations

    Trough plasma concentration is the measured concentration at the end of a dosing interval at steady state (taken directly before next administration). Blood samples were collected at specific timepoints to measure trough plasma concentrations of JTE-051 in the subjects randomized to JTE-051 treatment groups.

    Time frame: Week 12

08

Results

Posted Aug 6, 2021
Limitations and caveats
This study was terminated early as per the Sponsor decision.

Participant flow

Written informed consent was obtained prior to performing any study-related procedures. A copy of the informed consent was provided to each subject enrolled in this study. To qualify for the study, subjects were required to satisfy defined criteria.

Participant flow — Overall Study
MilestoneJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Started23332
Completed22111
Not completed01221
Withdrew: Study discontinued by sponsor01100
Withdrew: Adverse event00120
Withdrew: Withdrawal by subject00001

Outcome measures

PrimaryProportion of Subjects Achieving a Minimum 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI-75) by End-of-treatment (EOT).

The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-75 response rate is defined as at least 75 percent (%) reduction in PASI score relative to Baseline.

Time frame:
Up to 12 Weeks
Reported as:
Number · % of subjects achieving PASI-75
Proportion of Subjects Achieving a Minimum 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI-75) by End-of-treatment (EOT).
% of subjects achieving PASI-75JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Proportion of Subjects Achieving a Minimum 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI-75) by End-of-treatment (EOT).00000
SecondaryPercent Change From Baseline in PASI Score

The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percent change was calculated by taking the Week 12 PASI score and subtracting the baseline PASI, and dividing by the baseline PASI, then multiplying by 100 to get the percent change from baseline.

Time frame:
Week 12
Reported as:
Mean · % change in PASI Score
Percent Change From Baseline in PASI Score
% change in PASI ScoreJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Percent Change From Baseline in PASI Score-17.51 ± 3.120-27.69 ± 2.499-33.33 ± NA-34.09 ± 33.4290.00 ± NA
SecondaryProportion of Subjects Achieving PASI-50 (50% Improvement From Baseline in PASI)

The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-50 response rate is defined as at least 50 percent (%) reduction in PASI score relative to Baseline.

Time frame:
Week 12
Reported as:
Number · % of subjects achieving PASI-50
Proportion of Subjects Achieving PASI-50 (50% Improvement From Baseline in PASI)
% of subjects achieving PASI-50JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Proportion of Subjects Achieving PASI-50 (50% Improvement From Baseline in PASI)000500
SecondaryProportion of Subjects Achieving PASI-90 (90% Improvement From Baseline in PASI)

The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-90 response rate is defined as at least 90 percent (%) reduction in PASI score relative to Baseline.

Time frame:
Week 12
Reported as:
Number · % of subjects achieving PASI-90
Proportion of Subjects Achieving PASI-90 (90% Improvement From Baseline in PASI)
% of subjects achieving PASI-90JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Proportion of Subjects Achieving PASI-90 (90% Improvement From Baseline in PASI)00000
SecondaryProportion of Subjects Achieving PASI-100 (100% Improvement From Baseline in PASI)

The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. The PASI-100 response rate is defined as 100 percent (%) reduction in PASI score relative to Baseline.

Time frame:
Week 12
Reported as:
Number · % of subjects achieving PASI-100
Proportion of Subjects Achieving PASI-100 (100% Improvement From Baseline in PASI)
% of subjects achieving PASI-100JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Proportion of Subjects Achieving PASI-100 (100% Improvement From Baseline in PASI)00000
SecondaryProportion of Subjects Who Achieved Static Physician's Global Assessment (sPGA) Score of 0 or 1

The sPGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the redness, thickness and scaling across all psoriatic lesions. Average redness, thickness and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score is calculated as average of the 3 severity (redness, thickness and scaling) scores and rounded to the nearest whole number score to determine the sPGA score (0=cleared; 1=minimal; 2=mild; 3=moderate; and 4=severe). For this outcome measure, a score of 0 means no symptoms of psoriasis and a score of 1 means minimal symptoms of psoriasis.

Time frame:
Week 12
Reported as:
Number · % of subjects achieving sPGA 0 or 1
Proportion of Subjects Who Achieved Static Physician's Global Assessment (sPGA) Score of 0 or 1
% of subjects achieving sPGA 0 or 1JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Proportion of Subjects Who Achieved Static Physician's Global Assessment (sPGA) Score of 0 or 1000500
SecondaryChange From Baseline in Static Physician's Global Assessment (sPGA) Score

The sPGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the redness, thickness and scaling across all psoriatic lesions. Average redness, thickness and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score is calculated as average of the 3 severity (redness, thickness and scaling) scores and rounded to the nearest whole number score to determine the sPGA score (0=cleared; 1=minimal; 2=mild; 3=moderate; and 4=severe). Change from baseline to Week 12 in sPGA was calculated by taking the Week 12 sPGA and subtracting the baseline sPGA.

Time frame:
Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Static Physician's Global Assessment (sPGA) Score
score on a scaleJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Change From Baseline in Static Physician's Global Assessment (sPGA) Score0.0 ± 0.00-1.0 ± 0.000.0 ± NA-1.5 ± 0.710.0 ± NA
SecondaryPercent Change From Baseline in Psoriasis Body Surface Area (BSA)

The total body surface area (BSA) affected by plaque-type psoriasis was obtained from the percentages of areas affected, including head, trunk, upper limbs and lower limbs. Each reported percentage was multiplied by its respective body region corresponding factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) and the resulting 4 values were added up to obtain the total psoriasis BSA (Range: 0 to 100). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region surface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs. Percent change from baseline to Week 12 in BSA was calculated by taking the Week 12 BSA and subtracting the baseline BSA, then dividing by the baseline BSA and multiplying by 100. A negative change from baseline at Week 12 indicates a reduction in the Psoriasis BSA compared to the baseline.

Time frame:
Week 12
Reported as:
Mean · % change in Psoriasis BSA
Percent Change From Baseline in Psoriasis Body Surface Area (BSA)
% change in Psoriasis BSAJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Percent Change From Baseline in Psoriasis Body Surface Area (BSA)0.00 ± 0.000-20.02 ± 12.0990.00 ± NA-0.36 ± 0.5160.00 ± NA
SecondaryChange From Baseline in the Skindex-16 Overall Score

Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Overall scale score is an average of 16 items expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Overall Score was calculated by taking the Week 12 Skindex-16 Overall Score and subtracting the baseline Skindex-16 Overall Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.

Time frame:
Week 12
Reported as:
Mean · score on a scale
Change From Baseline in the Skindex-16 Overall Score
score on a scaleJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Change From Baseline in the Skindex-16 Overall Score-5.75 ± 15.486-14.10 ± 28.709-9.40 ± NA-20.80 ± 20.6486.20 ± NA
SecondaryChange From Baseline in the Skindex-16 Symptoms Scale Score

Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Symptoms scale score is an average of items 1 to 4 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Symptoms Scale Score was calculated by taking the Week 12 Skindex-16 Symptoms Scale Score and subtracting the baseline Skindex-16 Symptoms Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.

Time frame:
Week 12
Reported as:
Mean · score on a scale
Change From Baseline in the Skindex-16 Symptoms Scale Score
score on a scaleJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Change From Baseline in the Skindex-16 Symptoms Scale Score8.35 ± 0.071-14.60 ± 56.003-16.60 ± NA-10.40 ± 14.70816.60 ± NA
SecondaryChange From Baseline in the Skindex-16 Emotions Scale Score

Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform all responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Emotions scale score is an average of items 5 to 11 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Emotions Scale Score was calculated by taking the Week 12 Skindex-16 Emotions Scale Score and subtracting the baseline Skindex-16 Emotions Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.

Time frame:
Week 12
Reported as:
Mean · score on a scale
Change From Baseline in the Skindex-16 Emotions Scale Score
score on a scaleJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Change From Baseline in the Skindex-16 Emotions Scale Score-9.50 ± 0.000-14.30 ± 20.223-14.30 ± NA-23.85 ± 33.729-2.40 ± NA
SecondaryChange From Baseline in the Skindex-16 Functioning Scale Score

Skindex-16 questionnaire contains 16 questions related to quality of life in subjects with skin disease. It consists of a short 16-item assessment completed by the subject, with each item rated on a 7-point Likert scale (0=never bothered to 6=always bothered). Each raw score is multiplied by 16.667 to transform responses to a linear scale from 0 (no effect) to 100 (effect experienced all the time). Responses to the Skindex-16 are categorized into 3 subscales: symptom, emotional \& functional; their respective scores are expressed in a linear scale from 0 to 100. Functioning scale score is an average of items 12 to 16 expressed in a linear scale from 0 to 100. Change from baseline to Week 12 in the Skindex-16 Functioning Scale Score was calculated by taking the Week 12 Skindex-16 Functioning Scale Score and subtracting the baseline Skindex-16 Functioning Scale Score. A negative change from baseline at Week 12 indicates an improvement in the subject's condition compared to the baseline.

Time frame:
Week 12
Reported as:
Mean · score on a scale
Change From Baseline in the Skindex-16 Functioning Scale Score
score on a scaleJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Change From Baseline in the Skindex-16 Functioning Scale Score-11.65 ± 49.427-13.35 ± 18.8803.40 ± NA-25.00 ± 7.07110.00 ± NA
SecondaryNumber of Subjects With Treatment-emergent Adverse Events

Subjects in the Safety Population (13, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The study was terminated early as per the Sponsor decision. All randomized subjects were included in the Safety Population.

Time frame:
Up to 16 Weeks
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-emergent Adverse Events
ParticipantsJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Number of subjects with TEAEs02230
Number of subjects with no TEAEs21102
SecondaryJTE-051 Trough Plasma Concentrations

Trough plasma concentration is the measured concentration at the end of a dosing interval at steady state (taken directly before next administration). Blood samples were collected at specific timepoints to measure trough plasma concentrations of JTE-051 in the subjects randomized to JTE-051 treatment groups.

Time frame:
Week 12
Reported as:
Mean · ng/mL
JTE-051 Trough Plasma Concentrations
ng/mLJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mg
JTE-051 Trough Plasma Concentrations184 ± 70.751 ± 72.1377 ± NA203 ± 286.4

Adverse events

Collected over Up to 16 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
JTE-051 50 mg0/2 (0%)0/2 (0%)0/2 (0%)
JTE-051 100 mg0/3 (0%)0/3 (0%)2/3 (66.7%)
JTE-051 150 mg0/3 (0%)0/3 (0%)2/3 (66.7%)
JTE-051 200 mg0/3 (0%)0/3 (0%)3/3 (100%)
Placebo0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventJTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlacebo
Hypoaesthesia oralGastrointestinal disorders0/20/30/31/30/2
Ear infectionInfections and infestations0/21/30/30/30/2
GastroenteritisInfections and infestations0/21/30/30/30/2
Gastrointestinal infectionInfections and infestations0/20/31/30/30/2
Oral candidiasisInfections and infestations0/20/31/30/30/2
Tooth abscessInfections and infestations0/21/30/30/30/2
Blood creatine phosphokinase increasedInvestigations0/21/30/30/30/2
Transaminases increasedInvestigations0/21/30/30/30/2
Weight increasedInvestigations0/21/30/30/30/2
ArthralgiaMusculoskeletal and connective tissue disorders0/20/30/31/30/2

Baseline characteristics

Baseline characteristics results are reported for the Safety Population consisting of the randomized subjects who receive at least one dose of the study drug and have at least one post-randomization safety data: 13 subjects.

Age, Categorical
Age, Categorical(Participants)JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlaceboTotal
<=18 years000000
Between 18 and 65 years1333212
>=65 years100001
Sex: Female, Male
Sex: Female, Male(Participants)JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlaceboTotal
Female103206
Male130127
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlaceboTotal
Hispanic or Latino100102
Not Hispanic or Latino1332211
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlaceboTotal
American Indian or Alaska Native000000
Asian010001
Native Hawaiian or Other Pacific Islander000000
Black or African American001001
White2223211
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)JTE-051 50 mgJTE-051 100 mgJTE-051 150 mgJTE-051 200 mgPlaceboTotal
Canada121105
United States112228
09

Study locations

16 sites
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Center For Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • University of South Florida - Hospital
    Tampa, Florida 33612, United States
  • Atlanta Dermatology Vein and Research Center LLC
    Alpharetta, Georgia 30022, United States
  • Advanced Medical Research, PC
    Sandy Springs, Georgia 30328, United States
  • Advanced Clinical Research - Dermatology Center of Canyon County
    Nampa, Idaho 83651, United States
  • Clinical Research Advantage, Inc.
    Evansville, Indiana 47714, United States
  • Kansas City Dermatology P.A.
    Overland Park, Kansas 66215-2309, United States
  • Forest Hills Dermatology Group
    Forest Hills, New York 11375, United States
  • Radiant Research, Inc.
    Anderson, South Carolina 29621, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • Dermatology Treatment and Research Center
    Dallas, Texas 75230, United States
  • Karma Clinical Trials
    Saint John's, Newfoundland and Labrador A1A 4Y3, Canada
  • Mediprobe Research Inc.
    London, Ontario N5X 2P1, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • David Gratton's Private Practice
    Montreal, Quebec H3H 1V4, Canada
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Oct 2018, 11 months.

Results were first posted in Aug 2021, 2 years 9 months after primary completion. A results delay was requested in Nov 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2017
First posted
Nov 30, 2017
StartActual
Nov 10, 2017
Primary completionActual
Oct 29, 2018
CompletionActual
Oct 29, 2018
Results delay requested
Nov 6, 2019
Results first posted
Aug 6, 2021
Last update
Aug 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03358290
Lead sponsor
Akros Pharma Inc.
Responsible party
Sponsor
First posted
Nov 30, 2017
Start date
Nov 10, 2017
Primary completion
Oct 29, 2018
Completion
Oct 29, 2018
Results posted
Aug 6, 2021
Last update
Aug 6, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion